Gyre Therapeutics, Inc. GYRE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 95.1%-0.3pp | 95.4%-0.1pp | 95.5%-0.4pp | 95.9%-0.3pp | 96.2%-0.1pp | |
| Operating margin | -0.1%-10.0pp | 9.9%-1.4pp | 11.2%+2.1pp | 9.1%-1.2pp | 10.3%-5.0pp | |
| Returns | ||||||
| Return on invested capital | -0.1%-12.9pp | 12.8%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.7×-0.1× | 0.8×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4.6×-1.0× | 5.6×-0.6× | 6.2×+0.8× | 5.4×+1.8× | 3.6×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -14.8×-12.2× | -2.6×+0.2× | -2.7×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $1.11+7.9% | $1.03+4.8% | $0.98+9.4% | $0.90+34.1% | $0.67+7.9% | |
| Valuation | ||||||
| Market capitalization | $694.58M-4.7% | $680.11M+0.4% | $677.57M-1.8% | $689.9M-4.5% | $722.69M-30.4% | |
| Price / sales | 5.9×-1.3× | 5.8×-0.5× | 6.3×-0.4× | 6.8×-0.4× | 7.2×-2.6× | |
| Price / book | 6.9×-3.8× | 6.4×-0.2× | 6.6×-0.8× | 7.5×-3.1× | 10.6×-5.8× | |
| EV / EBITDA | 265.6×+206× | 46.1×+1.5× | 44.6×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gyre Therapeutics, Inc. (GYRE) runs a 95.1% gross margin and a -0.1% operating margin, with a 6.3% net margin.
- Where do Gyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Gyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
